Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517235 | 0.77 | ELOVL6 (0.46) | MAPTLMNAMEN1KMT2AGAA | |
| Brofoxine SCHEMBL61925 | 0.76 | PGR (0.59) | PGRNR3C1NR3C2AR | |
| Brofoxine SCHEMBL29710912 | 0.76 | PGR (0.59) | PGRNR3C1NR3C2AR | |
| SCHEMBL4120633 | 0.72 | ELOVL6 (0.42) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL5518253 | 0.72 | LMNA (0.44) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4162748 | 0.72 | LMNA (0.44) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL3883846 | 0.71 | POLB (0.43) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL5516094 | 0.71 | LMNA (0.42) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL30847598 | 0.70 | LMNA (0.47) | MAPTLMNAMEN1KMT2AGAA | |
| Brofoxine SCHEMBL4166335 | 0.69 | PGR (0.68) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268149-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-7192956-B2 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1515725-A4 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1531824-A4 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1531824-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | Wyeth (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1515725-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH | 2004-01-22 | — | — | US | disclosed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000230-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | MAPT 1080/4885LMNA 844/4885MEN1 402/4885 |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | NR5A1, MC1R, CYP17A1 | MAPT 821/4885LMNA 4684/4885MEN1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.